linafexor   Click here for help

GtoPdb Ligand ID: 14569

Synonyms: CS-0159 | CS0159
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Linafexor (CS0159) is a non-bile-acid agonist of the farnesoid X receptor (FXR) [1]. It is designed to mimic the pulsatile nature of physiological bile acid dynamics as an approach to reduce the risk of toxicity arising from sustained drug delivery.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 84.75
Molecular weight 571.43
XLogP 4.9
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1=CC(=C(C(=C1)Cl)C2=NOC(=C2COC3C[C@@H]4CC[C@H](C3)N4C5=CC(=C(C=C5)C6=NOC(=O)N6)F)C7CC7)Cl
Isomeric SMILES C1C[C@H]2CC(C[C@@H]1N2C3=CC(=C(C=C3)C4=NOC(=O)N4)F)OCC5=C(ON=C5C6=C(C=CC=C6Cl)Cl)C7CC7
InChI InChI=1S/C28H25Cl2FN4O4/c29-21-2-1-3-22(30)24(21)25-20(26(38-33-25)14-4-5-14)13-37-18-10-15-6-7-16(11-18)35(15)17-8-9-19(23(31)12-17)27-32-28(36)39-34-27/h1-3,8-9,12,14-16,18H,4-7,10-11,13H2,(H,32,34,36)/t15-,16+,18?
InChI Key CEEANZUSISGCJL-BYICEURKSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Linafexor (CS0159) was progressed as a clinical candidate for the treatment of liver injury, inflammation, and fibrosis in bile-acid-related diseases.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05082779 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159 Phase 1 Interventional Cascade Pharmaceuticals, Inc
NCT05591079 A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH Phase 2 Interventional Cascade Pharmaceuticals, Inc
NCT07282353 A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA Phase 3 Interventional Cascade Pharmaceuticals, Inc